Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

Completed · Early Phase 1

Conditions studied: Squamous Cell Carcinoma of the Oral Cavity

In brief

A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.

Key facts

Study ID: NCT03459729
Run by: Medical College of Wisconsin
People needed: 6
Starts: 2021-08-24
Expected to finish: 2022-02-16
Last updated by the study team: 2025-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Clinical diagnosis of oral cavity squamous cell cancer.
Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within 7 days of registration in order to continue study agent administration.
Clinical stage II-IVA (as defined by the American Joint Committee on Cancer, 8th Edition [see Amin, 2017]) and amenable to surgical resection
New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of 6 months following previous definite surgery
History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration
Study agent administration should start within 7 days of registration
Patient must receive administration of study agent for a minimum of 7 days
Zubrod Score/Eastern Cooperative Oncology Group (ECOG) Performance status < 2.
Age ≥ 18 years.
Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows:
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3;
Platelets ≥ 100,000 cells/mm\^3;
Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
Adequate renal and hepatic function within 14 calendar days prior to registration, defined as follows:
o Serum creatinine < 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14 calendar days prior to registration, determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)
Total bilirubin < 2 x the institutional upper limit of normal (ULN) within 14 calendar days prior to registration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the institutional ULN within 14 calendar days prior to registration
Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to registration, with the following required parameters:
Magnesium: > 0.9 mg/dl or < 3 mg/dl;
Calcium: > 7 mg/dl or < 12.5 mg/dl;
Glucose: > 40 mg/dl or < 250 mg/dl;
Potassium: > 3 mmol/L or < 6 mmol/L;
Sodium: > 130 mmol/L or < 155 mmol/L.
Female patients must meet one of the following:
Postmenopausal for at least one year before the screening visit, or

You may not qualify if…

History of active liver disease
Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus.
Concurrent use of any medicinal botanical, natural, or other herbal compound/s that the study PI believes could potentially impact the results/objectives of this study
Planned subtotal or debulking surgery, as determined by enrolling physician determination, is not permissible.
Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different cancer is allowable.
Prior radiotherapy for oral SCC is permissible if disease free for 1 year since prior oral cancer treatment and free of significant late radiation effects.
Severe active comorbidity such as uncontrolled cardiac disease, infection, severe Chronic Obstructive Pulmonary Disease (COPD).

Where it is running

Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.